Theravance Biopharma, Inc. (TBPH) financial statements (2020 and earlier)

Company profile

Business Address UGLAND HOUSE, SOUTH CHURCH STREET
GEORGE TOWN, GRAND CAYMAN, KY1-1104
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments281505349501172255
Cash and cash equivalents583788934511389
Short-term investments22312726015660165
Receivables2912120
Inventory, net of allowances, customer advances and progress billings  17121013
Inventory  17121013
Prepaid expense7174518 
Other undisclosed current assets221079358
Total current assets:338533379529237275
Noncurrent Assets
Operating lease, right-of-use asset47
Nontrade receivables4 8   
Property, plant and equipment13131081010
Long-term investments and receivables512421005151
Long-term investments512421005151
Restricted cash and investments111111
Deferred costs     1
Other noncurrent assets222211
Other undisclosed noncurrent assets0    (1)
Total noncurrent assets:7027631116362
TOTAL ASSETS:409560441639300338
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities454342243536
Accounts payable59621910
Accrued liabilities61012858
Employee-related liabilities282424141118
Interest and dividends payable6     
Deferred revenue32
Debt8     
Deferred revenue and credits0000
Contract with customer, liability43
Other liabilities     5
Other undisclosed current liabilities2712212515 
Total current liabilities:1129963494941
Noncurrent Liabilities
Long-term debt and lease obligation274225224223  
Long-term debt, excluding current maturities226225224223  
Operating lease, liability48
Liabilities, other than long-term debt2859401787
Deferred revenue and credits4455
Deferred revenue7
Contract with customer, liability26
Deferred rent credit 8
Other liabilities2125361332
Total noncurrent liabilities:30228426424087
Total liabilities:4133823262895748
Stockholders' equity
Stockholders' equity attributable to parent(224)(52)115350243290
Common stock0000  
Additional paid in capital1,025961914863565429
Accumulated other comprehensive income (loss)0(0)(1)(0)(0)(0)
Accumulated deficit(1,249)(1,012)(798)(512)(322)(139)
Total stockholders' equity:(224)(52)115350243290
Other undisclosed liabilities and equity219230    
TOTAL LIABILITIES AND EQUITY:409560441639300338

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues736015494212
Revenue, net151894
Cost of revenue
(Cost of Goods and Services Sold)
  (1)(0)(2)(7)
Gross profit:73601548405
Operating expenses(325)(299)(276)(229)(224)(244)
Other undisclosed operating income  1027
Operating loss:(252)(239)(260)(180)(182)(233)
Nonoperating income (expense)812(3)111
Investment income, nonoperating  (8)  (1)
Other nonoperating income8125112
Interest and debt expense(32)(10)(9)(1)  
Other undisclosed income from continuing operations before equity method investments, income taxes     1
Loss from continuing operations before equity method investments, income taxes:(275)(237)(272)(181)(181)(231)
Income from equity method investments3411    
Loss from continuing operations before income taxes:(242)(226)(272)(181)(181)(231)
Income tax expense (benefit)511(14)(10)(1)(6)
Net loss available to common stockholders, diluted:(236)(216)(285)(191)(182)(237)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(236)(216)(285)(191)(182)(237)
Comprehensive loss:(236)(216)(285)(191)(182)(237)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent01(0)(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(236)(215)(286)(191)(182)(237)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: